Evidence map›Paper›PMID 37140984›Full record

ArticleJCI insight2023

Time-dependent effects of endogenous hyperglucagonemia on glucose homeostasis and hepatic glucagon action.

Camila Lubaczeuski, Nadejda Bozadjieva-Kramer, Ruy A Louzada, George K Gittes, Gil Leibowitz, Ernesto Bernal-Mizrachi

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Camila LubaczeuskiDepartment of Medicine, Division Endocrinology, Metabolism and Diabetes, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Nadejda Bozadjieva-KramerVeterans Affairs Ann Arbor Healthcare System, Research Service, Ann Arbor, Michigan, USA.
Ruy A LouzadaDepartment of Medicine, Division Endocrinology, Metabolism and Diabetes, Miller School of Medicine, University of Miami, Miami, Florida, USA.
George K GittesChildrens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Gil LeibowitzDiabetes Unit and Endocrine Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Ernesto Bernal-MizrachiDepartment of Medicine, Division Endocrinology, Metabolism and Diabetes, Miller School of Medicine, University of Miami, Miami, Florida, USA.
University of Miami · USChildren's Hospital of Pittsburgh · USHadassah Medical Center · ILUniversity of Michigan · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Michigan Institute for Clinical and Health Research (MICHR)UM1TR004404 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Julie C Lumeng · 2023 to 2026
$39.8M
University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OWYANG, CHUNG · 1986 to 2021
$22.5M
AKT/mTOR Signaling and Regulation of Cell Cycle in beta CellsR01DK073716 · NIDDK · WASHINGTON UNIVERSITY · PI BERNAL-MIZRACHI, ERNESTO · 2006 to 2022
$4.6M
Obesity Surgery Scientist Training ProgramT32DK108740 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin Brigham Dimick, RANDY J SEELEY · 2016 to 2026
$2.2M
The role of intestinal-derived FGF15/19 during obesity and rapid weight lossIK2BX005715 · VA · VETERANS HEALTH ADMINISTRATION · PI KRAMER, NADEJDA BOZADJIEVA · 2022 to 2025
–
BLRD VA I01 BX002728BLRD VA IK2 BX005715NCATS NIH HHS UL1 TR002240NCATS NIH HHS UM1 TR004404NIDDK NIH HHS P30 DK034933NIDDK NIH HHS R01 DK073716NIDDK NIH HHS T32 DK108740
6 · The paper itself

Abstract

Elevation of glucagon levels and increase in α cell proliferation is associated with states of hyperglycemia in diabetes. A better understanding of the molecular mechanisms governing glucagon secretion could have major implications for understanding abnormal responses to hypoglycemia in patients with diabetes and provide novel avenues for diabetes management. Using mice with inducible induction of Rheb1 in α cells (αRhebTg mice), we showed that short-term activation of mTORC1 signaling is sufficient to induce hyperglucagonemia through increased glucagon secretion. Hyperglucagonemia in αRhebTg mice was also associated with an increase in α cell size and mass expansion. This model allowed us to identify the effects of chronic and short-term hyperglucagonemia on glucose homeostasis by regulating glucagon signaling in the liver. Short-term hyperglucagonemia impaired glucose tolerance, which was reversible over time. Liver glucagon resistance in αRhebTg mice was associated with reduced expression of the glucagon receptor and genes involved in gluconeogenesis, amino acid metabolism, and urea production. However, only genes regulating gluconeogenesis returned to baseline upon improvement of glycemia. Overall, these studies demonstrate that hyperglucagonemia exerts a biphasic response on glucose metabolism: Short-term hyperglucagonemia lead to glucose intolerance, whereas chronic exposure to glucagon reduced hepatic glucagon action and improved glucose tolerance.

Indexed as

Glucose IntoleranceHypoglycemiaAnimalsGlucagonGlucoseHomeostasisLiverMiceGlucagonGlucoseEndocrinologyGlucose metabolismIslet cellsMetabolism

Identifiers

PMID37140984
PMCPMC10393226
OpenAlexW4368356244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.